Janssen and BMS Present Results of Milvexian in P-II AXIOMATIC-TKR Study for the Treatment of TKR Surgery at AHA 2021, Published in NEJM

November 16, 2021 Auto Bot BMS, Clinical Trials, Janssen, NEJM, P-II 0

Shots:

  • The P-II AXIOMATIC-TKR study evaluates the efficacy and safety of milvexian (qd/bid) vs enoxaparin (SC) in 1242 patients with elective TKR surgery
  • The trial met both of its pre-specified proof-of-principle requirements i.e., milvexian (bid) showed significant efficacy, reduction in the risk of postoperative VTE in a dose-dependent manner without increasing the risk of bleeding compared with enoxaparin & demonstrated a favorable antithrombotic profile across multiple doses
  • Milvexian is an FXIa inhibitor for the prevention and treatment of major thrombotic conditions. The results from the ongoing P-II AXIOMATIC-SSP study of milvexian for secondary stroke prevention are expected in H1’22

Click here to­ read the full press release/ article | Ref: Janssen | Image: Reuters

The post Janssen and BMS Present Results of Milvexian in P-II AXIOMATIC-TKR Study for the Treatment of TKR Surgery at AHA 2021, Published in NEJM first appeared on PharmaShots.